Gary H. Gibbons, M.D. - November 15, 2012
This year's American Heart Association (AHA) Scientific Sessions, held Nov. 3-7 in Los Angeles, offered a wealth of new and provocative research findings and provided a welcome opportunity for those of us in the NHLBI scientific community to meet with our colleagues in cardiovascular research and clinical practice from around the world who are working to increase knowledge that can ultimately improve health for all. I was delighted to have had the opportunity to attend many of the sessions and was honored to have been involved in a few of them as a moderator and discussant.
I want to congratulate all of our NHLBI staff members who gave well-received presentations and moderated thoughtful panels. I also want to congratulate the many NHLBI-supported investigators who were recognized at the meeting, together earning more than 20 awards and giving distinguished lectures spanning basic, clinical, and population research. More than 40 current and former NHLBI-supported investigators and members of the National Heart, Lung, and Blood Advisory Council were named AHA Distinguished Scientists this year, a prestigious designation that "is bestowed on a select group of prominent scientists whose contributions to research have advanced our understanding of cardiovascular diseases and stroke." Also noteworthy was the international collaboration award given to the members of the Resuscitation Outcomes Consortium, or ROC, at the concurrent AHA Resuscitation Science Symposium on Nov. 3.
NHLBI staff and NHLBI-supported investigators also presented the results of several high-profile clinical trials and epidemiology studies that are likely to influence clinical practice, such as:
- Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM): Cardiac bypass surgery superior to non-surgical procedure for adults with diabetes and heart disease
- Transplantation in Myocardial Infarction Evaluation (TIME): Therapy with bone marrow-derived stem cells does not improve short-term recovery after heart attack
- Trial to Assess Chelation Therapy (TACT): Statement from NHLBI Director Gary H. Gibbons, M.D.
- The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (POSEIDON): [University of Miami] study in JAMA shows donor and patient stem cells can repair heart tissue
- Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARRESS): Ultrafiltration may not be best approach for heart failure patients
- Hispanic Community Health Study/Study of Latinos (HCHS/SOL) and Reasons for Geographic and Racial Differences in Stroke (REGARDS): Two NIH landmark studies show power of epidemiology research; underscore need to address health disparities
I believe that all of us are still processing the information we were exposed to at the meeting and eagerly await the opportunity to review many of the papers as they are published.
- YouTube video from AHAScienceNews: Cardiologists Elliott Antman, Frans Van de Werf, Gary H. Gibbons, and Alice Jacobs discuss the clinical implications of several late-breaking clinical trials presented at the AHA meeting on Nov. 4, 2012
- AHA Scientific Sessions 2012 website
- "Special cardiovascular issue" of the Journal of the American Medical Association, which contains many NHLBI-supported studies
- Daviglus, Martha L., et al. Prevalence of Major Cardiovascular Risk Factors and Cardiovascular Diseases Among Hispanic/Latino Individuals of Diverse Backgrounds in the United States. JAMA 2012; 308 (17): 1775-84.
- Safford, Monika M., et al. Association of Race and Sex With Risk of Incident Acute Coronary Heart Disease Events. JAMA 2012; 308 (17): 1768-74.
- Lauer, Michael S. Time for a Creative Transformation of Epidemiology in the United States. JAMA 2012; 308 (17): 1804-5.
- Farkouh, Michael E., et al. Strategies for Multivessel Revascularization in Patients with Diabetes. N Engl J Med 2012. Published online Nov. 4.
- Hare, Joshua M., et al. Comparison of Allogeneic vs Autologous Bone Marrow–Derived Mesenchymal Stem Cells Delivered by Transendocardial Injection in Patients With Ischemic Cardiomyopathy: The POSEIDON Randomized Trial. JAMA 2012; 1-11.